Ontada Names Jade Cusick Chief Commercial Officer

April 25, 2024

Experienced healthcare leader brings over two decades of expertise in life sciences industry.

BOSTON, Apr. 22, 2024 — Ontada®, a McKesson business dedicated to leveraging oncology real-world data and evidence, clinical education, and provider technology, announced the appointment of Jade Cusick as its new Chief Commercial Officer and member of the Ontada leadership team. In this role, Cusick will focus on spearheading client partnerships, commercialization, and growth initiatives, along with marketing activities across key customer segments and stakeholders.

With over two decades of experience in the life sciences industry, we are thrilled to welcome Jade to our team,” said Christine Davis, President, Ontada. “Jade brings a deep understanding of the importance of creating consistent quality, delivery, and customer engagement processes for our custom and product data offerings for our customers.”

In his most recent role, Cusick held the role of Chief Commercial Officer at Aetion. Prior to that, he held the Chief Commercial Officer role and served on the executive committee of Cerner Enviza, an Oracle company, where he led client partnerships and commercialization efforts.

“With its’ diverse portfolio of solutions, Ontada is uniquely positioned to help improve health outcomes of those impacted by cancer, from helping to accelerate the research and development to offering a broad range of products and services across the value chain” said Cusick. “I’m excited to join the McKesson team as we deliver on our mission of improving health outcomes for those impacted by cancer.”

About Ontada®

Ontada is an oncology technology and insights business dedicated to transforming the fight against cancer. Part of McKesson Corporation, Ontada was founded on the core belief that precise insights – delivered exactly at the point of need – can save more patients’ lives. We connect the full patient journey by combining technologies used by The US Oncology Network and other community oncology providers with real-world data and research relied on by all top 15 global life sciences companies. Our work helps accelerate innovation and powers the future of cancer care. For more information, visit ontada.com.

About McKesson Oncology and Specialty Solutions

It’s an unprecedented time for patients living with cancer as life sciences companies race to create new, cutting-edge therapies. With cancer care becoming more targeted, providers, life sciences companies, and payers face a multitude of challenges and complexity in the development of new treatments and making them accessible to patients in need. At McKesson, our unmatched portfolio of oncology businesses and partners provide research, insights, technologies, and services that are helping to address these hurdles and improve cancer and specialty care.

  • McKesson is fueling discovery by helping patients participate in cutting-edge clinical trials closer to home through the joint venture between US Oncology Research and Sarah Cannon Research Institute.
  • The US Oncology Network and McKesson Provider Solutions are advancing specialty care and high-quality cancer care in the communities where patients live by supporting the practices of thousands of independent, community-based providers.
  • Ontada®, a McKesson business dedicated to oncology, generates real-world data (RWD) and real-world evidence (RWE) and provides clinical education and provider technology to inform and improve cancer care.
  • As one of the largest distributors of oncology and specialty medicines, we are ensuring medicines make their way to those who are counting on them.

And through CoverMyMeds, Biologics by McKesson, and GPO services, our work continues to help patients access, afford, and adhere to their medicines.